What to Know About the 2nd ADC Toxicity Summit
The 2nd ADC Toxicity Summit returned for a second year as the only ADC event purely focused on improving prediction and translation of ADC toxicities from preclinical studies through to the clinic.
By gaining deeper insights into the mechanisms underlying specific toxicities, the translation of these toxicities from in vitro to in vivo settings, as well as investigating alternative models for toxicity evaluation, this was the perfect opportunity to stay ahead of this evolving field to steer you towards IND and BLA approval.
Considering the insights into overcoming in vivo and in vitro translational challenges, as well as the clinical perspectives into mitigating and managing toxicities, there had never been a better time to attend the 2nd ADC Toxicity Summit . With talks from the leading minds in ADC toxicology this was an opportunity to join the dedicated community to engage in in-depth conversations to make meaningful strides forward in developing safer ADCs to advance them to clinic and improve patient outcomes.
What you Missed:
Improve the predictability of your off-target toxicities from in vivo to the clinic alongside Mersana Therapeutics & Sutro Biopharma, through the exploration of ADC platform optimization as well as target selection to minimize toxicities
Investigate the mechanisms of hematotoxicities to enable ADC toxicity differentiation & delve into in vitro toxicity models for the early identification and mitigation of potential adverse effects associated with ADC development, with Merck & Oxford Biotherapeutics
Address the NHP shortage by refining in vivo toxicity study designs and exploring alternative humanized mouse models for improved clinical toxicity prediction, in collaboration with AbbVie and Pfizer
Explore ocular toxicities associated with ADCs & explore preclinical models to evaluate toxicities with ImmunoGen & discover the potential of biomarkers for improved tolerability & patient selection strategies with Daiichi Sankyo
Who Joined Us:
Uniting over 80 experts spanning toxicology, pathology, translational sciences, preclinical development, pharmacology, and biology, this exclusive gathering fostered profound discussions aimed at advancing the development of safer ADCs. This niche community connected over 3 days to leverage collective expertise and to drive progress in the prevention of toxicities.
What Your Peers Had to Say:
“The conference focused on a critical topic which is not adequately covered in published literature. The speakers covered both program specific and more general aspects of ADC toxicity. Companies are often not willing to discuss toxicity but the speakers disclosed previously unpublished aspects of their work. Overall a very worthwhile three days.” - Philip Huxley, Vice President, Oncology, Bicycle Therapeutics
“This was a great conference and was a nice size which facilitated lots of networking and interaction.” - Estelle McLean, Team Leader, Almac
“It was a great opportunity to exchanges with peers in the field of ADC development and with experts in the field.” - Frederique Brune, Managing Director, Mablink
“Real tox data influencing the drug development, and retrospective analysis for tox events and drug development” - Katsu Ishida, Senior Director, Toxicology, Mersana
